5
Artillegence Bio-Innovations
512642 BSE
Artillegence Bio-Innovations
Financial Services BSE: 512642 Finance
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Stock is trading at 0.10 times its book value
Weaknesses
4- The company has delivered a poor sales growth of -27.2% over past five years.
- Company has a low return on equity of -0.35% over last 3 years.
- Company has high debtors of 260 days.
- Working capital days have increased from 1,486 days to 3,178 days
Growth Rate
Revenue Growth
-93% lower than
3Y
Net Income Growth
-100%
Quarterly Results
| Particulars | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.28 | 0.21 | 0.03 | 0.03 | 0.02 | 0 | 0.02 | 0.7 | 0 | 0 | 0.01 | 0.04 | 0 |
| Expenses | 0.28 | 0.22 | 0.01 | 0.03 | 0.02 | 0 | 0.01 | 0.7 | 0 | 0 | 0 | 0.04 | 0.01 |
| Operating Profit | 0 | -0.01 | 0.02 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0.01 | 0 | -0.01 |
| OPM % | 0% | -4.76% | 66.67% | 0% | 0% | — | 50% | 0% | — | — | 100% | 0% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | -0.01 | 0.02 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0.01 | 0 | -0.01 |
| Tax % | — | 0% | 0% | — | — | — | 0% | — | — | — | 0% | — | 0% |
| Net Profit | 0 | -0.01 | 0.02 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0.01 | 0 | -0.01 |
| EPS in Rs | 0 | -0.01 | 0.03 | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0.01 | 0 | -0.01 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 8.42 | 11.55 | 4.44 | 9.9 | 11.8 | 9.57 | 2.36 | 0.05 |
| Expenses | 8.43 | 11.55 | 4.45 | 9.91 | 11.8 | 9.91 | 2.37 | 0.05 |
| Operating Profit | -0.01 | 0 | -0.01 | -0.01 | 0 | -0.34 | -0.01 | 0 |
| OPM % | -0.12% | 0% | -0.23% | -0.1% | 0% | -3.55% | -0.42% | — |
| Other Income | 0.01 | 0 | 0.01 | 0.02 | 0 | 0.06 | 0.01 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | 0.01 | 0 | -0.28 | 0 | 0 |
| Tax % | — | — | — | 0% | — | 0% | — | — |
| Net Profit | 0 | 0 | 0 | 0.01 | 0 | -0.28 | 0 | 0 |
| EPS in Rs | 0 | 0 | 0 | 0.01 | 0 | -0.38 | 0 | 0 |
| Div. Payout % | — | — | — | 0% | — | 0% | — | — |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 7.32 | 7.32 | 7.32 | 7.32 | 7.32 | 7.32 | 7.32 |
| Reserves | 19.29 | 19.29 | 19.29 | 19.3 | 19.31 | 19.03 | 19.03 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.05 | 0.03 | 4.7 | 12.56 | 8.83 | 0.69 | 0 |
| Total Liabilities | 26.66 | 26.64 | 31.31 | 39.18 | 35.46 | 27.04 | 26.35 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1.58 | 0.9 | 1.15 | 17.59 | 6.64 | 8.37 | 5.76 |
| Other Assets | 25.08 | 25.74 | 30.16 | 21.59 | 28.82 | 18.67 | 20.59 |
| Total Assets | 26.66 | 26.64 | 31.31 | 39.18 | 35.46 | 27.04 | 26.35 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Operating | -0.02 | -0.07 | -0.43 | 16.63 | -10.56 | — | — |
| Investing | 0 | 0.68 | -0.26 | -16.44 | 10.95 | — | — |
| Financing | 0 | 0 | 0 | 0 | 0 | — | — |
| Net Cash Flow | -0.02 | 0.61 | -0.69 | 0.19 | 0.39 | — | — |
| Free Cash Flow | -0.02 | -0.07 | -0.43 | 16.63 | -10.56 | — | — |
| CFO/OP | 200 | — | 4,300 | -1,66,300 | — | — | — |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 322 | 144 | 228 | 41.29 | 22.27 | 64.08 | 260 |
| Inventory Days | 130 | 159 | 773 | 63.85 | 293 | 162 | 1,285 |
| Days Payable | 0.87 | 0 | 0 | 192 | 49.35 | 26.29 | 0 |
| Cash Conversion Cycle | 451 | 303 | 1,001 | -87.14 | 266 | 200 | 1,544 |
| Working Capital Days | 1,078 | 788 | 2,086 | 323 | 598 | 683 | 3,178 |
| ROCE % | — | 0% | 0% | 0.04% | 0% | -1.06% | 0% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Artillegence Bio-Innovations insights
45 extracted metrics + investor summaries across FY06–FY12.
Documents
1
Updates
21 February 2026 - Applied (10 Feb 2026) to reclassify promoters: Jyoti Kuthari 14,58,567 (0.94%); R. Suchanti 20,000 (0.01%); V. K. Jain 2,000 (0.01%). 21 February 2026 - Applied (10 Feb 2026) to reclassify promoters: Jyoti Kuthari 14,58,567 (0.94%); R. Suchanti 20,000 (0.01%); V. K. Jain 2,000 (0.01%).
2
Copy of Newspaper Publication
19 February 2026 - Unaudited financial results for quarter/nine months ended 31 Dec 2025 published 17 Feb 2026. 19 February 2026 - Unaudited financial results for quarter/nine months ended 31 Dec 2025 published 17 Feb 2026.
3
Outcome of Board Meeting
13 February 2026 - Board approved Q3 (31-Dec-2025) unaudited results; auditor disclaimed opinion for missing documents, unsupported sales, inventory, loans. 13 February 2026 - Board approved Q3 (31-Dec-2025) unaudited results; auditor disclaimed opinion for missing documents, unsupported sales, inventory, loans.
4
Outcome of Board Meeting
13 February 2026 - Board approved unaudited results for quarter ended 31 Dec 2025; auditor issued disclaimer citing missing records. 13 February 2026 - Board approved unaudited results for quarter ended 31 Dec 2025; auditor issued disclaimer citing missing records.
5
Appointment
10 February 2026 - Appointed Tarunkumar Dineshbhai Sindhav (DIN 11499512) as Additional Independent Director on 10/02/2026, subject to shareholder approval. 10 February 2026 - Appointed Tarunkumar Dineshbhai Sindhav (DIN 11499512) as Additional Independent Director on 10/02/2026, subject to shareholder approval.
Frequently Asked Questions about Artillegence Bio-Innovations
What does Artillegence Bio-Innovations Ltd do?
Artillegence Bio-Innovations Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, the company is engaged in finance and investment businesses.
Where is Artillegence Bio-Innovations Ltd (512642) listed?
Artillegence Bio-Innovations Ltd trades under code 512642 on the BSE.
Which sector does Artillegence Bio-Innovations Ltd belong to?
Artillegence Bio-Innovations Ltd is classified under the Financial Services sector, in the Finance industry.
Company Information
Artillegence Bio-Innovations Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, the company is engaged in finance and investment businesses.
Website artillegencebio.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/512642.md for Artillegence Bio-Innovations Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.